Sagimet to Present 52-Week Denifanstat Data at KOL Event
FOSTER CITY, Calif. — September 28, 2026 Sagimet Biosciences Inc. announced that it will host a virtual key opinion...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FOSTER CITY, Calif. — September 28, 2026 Sagimet Biosciences Inc. announced that it will host a virtual key opinion...
FOSTER CITY, Calif. — August 25, 2026 Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat...
FOSTER CITY, Calif., August 13, 2026 Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has...
